AI
IMUX icon

ArchPoint Investors’s Immunic IMUX Stock Holding History

ArchPoint Investors’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-75
Closed -$184K – 92
2016
Q3 		$184K Hold
75
– – 0.11% 83
2016
Q2 		$186K Hold
75
– – 0.11% 79
2016
Q1 		$272K Hold
75
– – 0.15% 72
2015
Q4 		$346K Buy
+75
New +$245K 0.24% 64

Other funds holding IMUX

Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ArchPoint Investors's IMUX Position: Q4 2016 in Review

ArchPoint Investors sold out of Immunic (IMUX) in Q4 2016, closing a stake of 75 shares — an estimated $184K sold.

ArchPoint Investors first reported a position in IMUX in Q4 2015 and held it in 4 quarters. The position peaked at $346K in Q4 2015. 55 funds tracked by Wall St. Rank hold IMUX as of Q4 2016.

  • ArchPoint Investors reported no remaining Immunic position as of Q4 2016 after selling out during the quarter.
  • ArchPoint Investors sold 75 Immunic shares in Q4 2016, an estimated $184K.
  • ArchPoint Investors first reported a position in Immunic in Q4 2015 and held it in 4 quarters.
  • ArchPoint Investors's Immunic position peaked at $346K in Q4 2015.
  • 55 funds tracked by Wall St. Rank held Immunic as of Q4 2016.

Based on ArchPoint Investors's 13F filing for Q4 2016, filed 14 Feb 2017.